Corvus Pharmaceuticals (CRVS) Form 3: Director reports no holdings

Corvus Pharmaceuticals, Inc. (CRVS) filed an Initial Statement of Beneficial Ownership (Form 3) reporting that David Scott Moore is a director and that, as of the 10/02/2025 event date, no securities are beneficially owned by him.

Rhea-AI Filing Summary

Corvus Pharmaceuticals, Inc. (CRVS) filed an Initial Statement of Beneficial Ownership (Form 3) reporting that David Scott Moore is a director and that, as of the 10/02/2025 event date, no securities are beneficially owned by him. The filing was signed on 10/06/2025 by an attorney-in-fact and includes a power of attorney exhibit.

Positive

• Disclosure completed for a director under Section 16
• No reportable securities owned by the director as of 10/02/2025

Negative

• None.

Insights

Corporate Governance Analyst

Director appointment shows governance disclosure with no immediate equity stake.

As reported, David Scott Moore is identified as a director and filed an initial Form 3 that states no securities are beneficially owned as of the 10/02/2025 event date. This indicates he held no reportable equity or derivative positions at that cut-off.

Key dependencies include any subsequent Form 4 filings if equity is later acquired; investors should note the signature date 10/06/2025 and expect additional Section 16 reporting if holdings change within statutory windows.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Form 3 for Corvus Pharmaceuticals (CRVS) report?

The Form 3 reports that David Scott Moore, identified as a director, does not beneficially own any securities as of 10/02/2025.

When was the Form 3 signed for the CRVS filing?

The filing was signed by an attorney-in-fact on 10/06/2025.

Does this Form 3 show any stock options or derivative holdings for CRVS director?

No. The filing explicitly states no securities are beneficially owned, and no derivative or option positions are listed.

Will there be additional filings if the director acquires shares?

Yes. Any subsequent acquisition by the director would typically be reported on a Form 4 under Section 16 within the required reporting window.

Who signed the Form 3 for David Scott Moore?

The Form 3 was signed as /s/ Leiv Lea, as Attorney-in-Fact for David Scott Moore on 10/06/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/06/2025 - 04:32 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Moore David Scott

(Last) (First) (Middle)

C/O CORVUS PHARMACEUTICALS, INC.

901 GATEWAY BOULEVARD, THIRD FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/02/2025

3. Issuer Name and Ticker or Trading Symbol
Corvus Pharmaceuticals, Inc. [ CRVS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Leiv Lea, as Attorney-in-Fact for David Scott Moore	10/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.